Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  API >  Hormones and the Endocrine System >  Sex Hormone Drugs >  UROFOLLITROPIN

UROFOLLITROPIN

Basic information Safety Supplier Related

UROFOLLITROPIN Basic information

Product Name:
UROFOLLITROPIN
Synonyms:
  • Fertinex
  • Fertinorm
  • Metrodin
  • Orgafol
  • UROFOLLITROPIN
  • FshUrofollitropin
  • 1-[19-amino-7-(2-amino-2-oxoethyl)-13-butan-2-yl-10-(1-hydroxyethyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]pyrrolidine-2-carboxamide
  • UROFOLLITROPIN USP/EP/BP
CAS:
97048-13-0
MF:
C42H65N11O12S2
MW:
980.16
Mol File:
97048-13-0.mol
More
Less

UROFOLLITROPIN Chemical Properties

solubility 
Soluble in water.
CAS DataBase Reference
97048-13-0
More
Less

UROFOLLITROPIN Usage And Synthesis

Chemical Properties

Almost white or slightly yellowish powder.

Uses

Hormone (follicle-stimulating).

brand name

Bravelle (Ferring Pharmaceuticals); Fertinex (Serono); Metrodin (Serono).

Clinical Use

Urofollitropin, a natural product like the menotropins, is obtained from the urine of postmenopausal women and then highly purified so as to contain only FSH, reportedly with only minute amounts of LH. Urofollitropin is used for its ability to stimulate follicle development, such as in women undergoing drug-induced pituitary suppression (GnRH antagonist or superagonist) for purposes of IVF (i.e., multiple follicle development or egg donation). When the number and size of the ovarian follicles are correct, as determined by ultrasound, hCG is administered so as to effect ovulation, and the oocytes are retrieved for IVF.
This drug also is indicated for women who have infertility caused by polycystic ovary syndrome, which generally is observed clinically as enlarged, cystic ovaries containing relatively small follicles. These patients often develop hirsutism, their androgen and LH levels appear elevated while their FSH levels are low, and the early exposure to these improper hormone levels may be causing the follicular atresia. The patient's monthly cycle is controlled by previous pituitary suppression via treatment with a GnRH superagonist or antagonist; urofollitropin, as an exogenous source of FSH, is administered and stimulates follicle maturation to preovulatory size, with little or no exposure of the follicles to additional LH. When the follicles have matured to preovulatory size, ovulation is assisted by the administration of hCG. The couple is then advised to engage in sexual intercourse daily, beginning on the day before hCG administration and until ovulation has occurred.

UROFOLLITROPINSupplier

Shanghai Techwell Biopharmacieutical Co., Ltd Gold
Tel
021-54427100-161
Email
sales@techwellpharma.com
NCE Biomedical Co.,Ltd.
Tel
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988
Nanjing Sunlida Biological Technology Co., Ltd.
Tel
025-57798810
Email
sales@sunlidabio.com
Watson Biotechnology Co.,Ltd
Tel
027-027-59207879 18140587686
Email
kf@3600chem.com
Shanghai YuanYe Biotechnology Co., Ltd.
Tel
021-61312847; 18021002903
Email
3008007409@qq.com